Although inhibitors of Bcl-2 and Bcl-xL are effective in treating hematopoietic malignancies [17], efficacy is limited in primary solid cancers including GC partly because of a complex microenvironment that promotes cancer cell survival and resistance to treatment. Here, BCL2L1 is linked to cancer.